Pablo Corral/LinkedIn
Oct 29, 2025, 07:39
Pablo Corral: Pushing the Limits of LDLc: Emerging Paradigms in CV Risk Reduction
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on LinkedIn:
“Pushing the limits of LDLc: Emerging paradigms in CV risk reduction
- Modern guidelines now target LDL-C <55 mg/dL, and even <40 mg/dL for the highest-risk patients.
- Evidence from FOURIER, ODYSSEY, and IMPROVE-IT confirms that the lower, the better — with no safety concerns, even below 25 mg/dL.
- Genetic data (PCSK9 LoF, APOB, ANGPTL3) reinforce that lifelong low LDL-C protects against ASCVD.
- Emerging therapies — PCSK9 inhibitors, inclisiran, bempedoic acid, ANGPTL3 inhibitors — make these targets achievable.
- Cognitive, endocrine, and hemorrhagic risks remain none at very low LDL-C.
The real challenge is no longer how low can we go, but how many actually get there.”
Stay updated with Hemostasis Today.
-
Dec 17, 2025, 06:28Wolfgang Miesbach on Linus Völker’s Presentation of Caplacizumab as Frontline Therapy for iTTP
-
Dec 17, 2025, 06:11Lisa Murphy Thanks Stroke Foundation Team for An Impactful, Rewarding and Incredible Year
-
Dec 17, 2025, 06:05Emmanuel J Favaloro Shares A Study on AI and Machine Learning in Thrombosis and Hemostasis
-
Dec 17, 2025, 05:54Michael Bruckman: Fantastic to See Platelet-Inspired Nanoparticles Gaining Attention!
-
Dec 17, 2025, 04:00Peter Verhamme on Genetic Predisposition to Thromboembolism and COVID
-
Dec 16, 2025, 17:14Piotr Czempik Honored for His Work on Cost Reduction in Blood Transfusions
-
Dec 16, 2025, 17:06Davood KHoda Amorzideh on VTE and Bleeding in Cancer
-
Dec 16, 2025, 16:56Kathryn Mikkelsen on The Beat: Vasculearn Network’s Newsletter for Clot Survivors
-
Dec 16, 2025, 16:50Raul Santos on Sex-Specific Biology and Plasma Fructose Levels in Cardiovascular Risk